Fundz
Funding, M&A and exec moves matched to your market — guaranteed to pay for itself in a year, or we refund it. See terms for full details.See plans →

Abcuro, Inc. raises $66 million in Series D financing led by New Leaf Venture Partners to advance its first-in-class medicine for Inclusion Body Myositis.

PRIVATEAug 18, 2026•about 6 hours ago

Amount Raised

$66 Million

Round Type

Series D

NewtonBiotechnologyHealth CareTherapeutics

Investors

Ra CapitalMass General Brigham VenturesRedmile GroupSamsara Bio CapitalBain Capital Life SciencesAbrdn Inc.New Leaf Venture Partners

Description

Abcuro, Inc. has successfully closed a $66 million Series D financing. The round was led by New Leaf Venture Partners, with participation from existing investors including abrdn Inc., Bain Capital Life Sciences, and others. The funds will be used to advance its medicine in development for Inclusion Body Myositis

Company Information

Company

Abcuro

Location

Newton, Texas, United States

About

Abcuro, based in Newton MA, is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T and NK cells. The company is conducting two clinical trials in rare diseases: a Phase 2/3 registrational trial evaluating ABC008 in inclusion body myositis (IBM,) and a Phase 1/2 trial evaluating ABC008 in T cell large granular lymphocytic leukemia. For more information, visit us on LinkedIn and at abcuro.com.

Don't miss Abcuro's next move

Get an email the moment Abcuro raises, hires an exec, or expands — usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Abcuro's next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.